We compared the in vivo and in vitro activities of CS-940, a new fluoroquinolone, with those of a group of other drugs. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC 90 s) of 0.5 g/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC 90 of 16 g/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.
Fluoroquinolones, such as ciprofloxacin and ofloxacin, were developed as broad-spectrum antibacterial agents against several pathogens, such as Staphylococcus aureus and Pseudomonas aeruginosa, and have high levels of bactericidal activity (11, 13) . These antibacterial agents were introduced into clinical practice for use in respiratory and urinary infections. However, since they show only moderate activities against gram-positive bacteria, the development of new quinolones continued in order to improve antibacterial activity against these organisms. On the other hand, tosufloxacin and sparfloxacin, which have higher in vitro levels of activity against gram-positive bacteria than other available fluoroquinolones, have potentially serious side effects such as photocytotoxicity (2, 5, 6, 8) . CS-940 {1-cyclopropyl-6-fluoro-8-difluoromethoxy-1,4-dihydro-7-[(3S)-methyl-1-piperazinyl]-4-oxo-3-quinolinecarboxylic acid hydrochloride} is a new fluoroquinolone developed by both Sankyo Co., Ltd., Tokyo, Japan, and Ube Industries, Ltd. M. Nakashima reported that the drug did not cause any side effects in phase one studies at the explanatory meeting held in Tokyo in 1995 (10a) .
In the present study, we compared the in vitro and in vivo activities of CS-940 with those of other antibacterial agents, including ciprofloxacin, tosufloxacin, levofloxacin, cefdinir, and amoxicillin, against bacteria isolated from patients with a variety of respiratory infections.
The following antimicrobial agents were obtained from the indicated sources: CS-940, Sankyo Co.; ciprofloxacin, Bayer Yakuhin (Osaka, Japan); tosufloxacin, Toyama Chemical Co. (Tokyo, Japan); sparfloxacin, Dainippon Pharmaceutical Co. (Osaka, Japan); levofloxacin, Daiichi Pharmaceutical Co. (Tokyo, Japan); cefdinir and amoxicillin, Fujisawa Pharmaceutical Co. (Osaka, Japan).
The clinical isolates tested in the present study were obtained from hospitals in several areas across Japan during 1991 and 1995. All organisms had been previously identified by routine laboratory methods and stored at Ϫ80°C.
The MICs for nonfastidious organisms were determined by the broth microdilution method as described in the guidelines of the Japanese Society for Chemotherapy (3, 4) . We used cation-adjusted Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) with appropriate concentrations of the divalent cations Ca 2ϩ and Mg 2ϩ for nonfastidious aerobic bacteria. The broth was supplemented with 5% lysed horse blood for fastidious organisms such as Streptococcus spp. and Moraxella catarrhalis. We also used cation-adjusted Mueller-Hinton broth supplemented with 5% lysed horse blood, 5 mg of yeast extract (Oxoid, Basingstoke, England) per ml, and 15 g of NAD (Sigma Chemical Co., St. Louis, Mo.) per ml for Haemophilus influenzae. The MIC for Bordetella pertussis was determined by the agar dilution method with a Bordet-Gengou medium base (Difco) supplemented with 15% horse blood and 1% glycerol. Bacterial suspensions were diluted with saline to concentrations of approximately 10 6 CFU/ml. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Toho University School of Medicine. Four-week-old male Slc/ICR mice (weight, 18 to 20 g; Sankyo Labo Service) were used in groups of eight unless otherwise indicated. Streptococcus pneumoniae was cultured in Todd-Hewitt broth (Difco) mixed with 30% horse serum at 35°C for 5 h, and organisms were harvested by centrifugation and then suspended in a predetermined volume of saline. A volume of 0.05 ml of bacterial suspension containing 7.4 ϫ 10 7 CFU of penicillin-susceptible S. pneumoniae TUH39 per ml (MIC of penicillin G, 0.016 g/ml) was instilled intranasally into ketamine-xylazine-anesthetized mice. These inocula caused 100% mortality in untreated animals 72 to 100 h after infection. Antimicrobial drugs were administered orally twice a day for 3 days, starting 20 h after intranasal instillation. This protocol was based on data obtained in preliminary experiments. The total number of living mice at each dose level was recorded on day 7 after infection. The 50% effective dose (ED 50 ) of each drug was calculated by the probit method (9) .
Five-week-old female CBA/J mice (weight, 15 to 17 g; Japanese Charles River) were anesthetized with ketamine-xylazine, then infected by intranasal instillation of penicillin-resistant S. pneumoniae TUM741 (MIC of penicillin G, 1.0 g/ml; 1.7 ϫ 10 6 CFU/mouse) (12) . Oral administration of the anti-bacterial drugs commenced 40 h after infection; drugs were given three times a day for 3 days. The commencement of drug therapy after 2 days was based on the time required for the development of murine pulmonary infection. Preliminary experiments showed that administration of the test drugs three times a day, but not twice a day, allowed the comparison of in vivo activities of these drugs in this model. Another group of mice, which were intranasally instilled with 40 l of 1% formalin 3 days before infection, were anesthetized with ketamine-xylazine and instilled intranasally with 0.05 ml of a suspension of cell-bound organisms of non-penicillinase-producing H. influenzae TUM8 (1.98 ϫ 10 5 CFU/ml); therapy commenced 40 h after intranasal instillation, and drugs were given twice a day for 3 days (10). This regimen was based on a series of preliminary experiments. Animals were sacrificed 20 h after the last administration of the test drug in order to minimize the effect of the drug administered, and the infected tissues were dissected and homogenized. The numbers of viable organisms were determined by agar plating. Evaluation of efficacy was based on the proportional reduction of bacterial counts in infected tissues of treated animals, compared with those in infected tissues of untreated control animals. Significant differences were established by using the Bonferroni multiple comparison test.
For pharmacokinetics studies, groups of three mice each received, one day after infection with S. pneumoniae TUH39, an oral antibiotic at a single dose of 50 mg/kg of body weight. Tissue samples of heart, blood, and lungs were obtained 5, 15, 30, 60, 120, 240, and 360 min after drug administration. The lungs were lightly washed with saline in order to minimize blood contamination. The levels of the biologically active form of the drug in serum and lungs were determined by a paper disk method with Escherichia coli K12 as the indicator organism incorporated into the medium (nutrient agar; Eiken).
In vitro activities of CS-940 and other drugs tested against clinical isolates are shown in Tables 1 to 3 . CS-940 exhibited potent activity against methicillin-susceptible S. aureus, with the MIC at which 90% of the strains were inhibited (MIC 90 ) being 0.125 g/ml. Against this pathogen, CS-940 was more effective than ciprofloxacin, levofloxacin, cefdinir, and amoxicillin and was comparable to tosufloxacin and sparfloxacin in effectiveness. Moreover, for methicillin-resistant S. aureus, the MIC 90 of CS-940 was 16 g/ml, making it twice (or more) as active as other drugs. CS-940 was twice (or more) as active as comparable quinolones against Streptococcus pyogenes. The MIC 90 s of CS-940 against Streptococcus agalactiae and penicillin-susceptible and -resistant S. pneumoniae were 0.25 to 0.5 g/ml; these values were twofold or more lower than those of all comparable agents except tosufloxacin. Against M. catarrhalis, CS-940 and the comparable new quinolones were highly active. The MIC 50 of CS-940 against S. pneumoniae was as low as 1 g/ml, in contrast to a MIC 90 of 32 g/ml. Its activity was the same as that of levofloxacin. CS-940 displayed a high degree of activity against H. influenzae and B. pertussis, with MIC 90 s ranging from 0.016 to 0.063 g/ml; these MIC 90 s were comparable to those of other new quinolones.
The area under the concentration-time curve (AUC) of sparfloxacin in serum was superior to those of others ( Table 4) . The half-lives of sparfloxacin in serum and lungs were longer than those of other drugs. However, the AUC and the maximum concentration (C max ) of CS-940 in lungs were superior to those of sparfloxacin and levofloxacin. In murine infections caused by penicillin-susceptible S. pneumoniae TUH39, the ED 50 of CS-940 was 13 mg/kg, which was the lowest among the tested antimicrobials, although the in vitro activity of CS-940 was similar to that of tosufloxacin ( Table 5 ). The recovery of CFU from the lungs of untreated mice infected with penicillin-resistant S. pneumoniae TUM741 ranged from 6.04 to 9.23 log CFU/lung (Table 6 ). Treatment with CS-940 at a dose of 50 mg/kg resulted in a significant reduction in the number of organisms in the lungs (P Ͻ 0.05) compared with those in untreated animals and in ciprofloxacinand levofloxacin-treated mice. On the other hand, the recovery of organisms from the lungs of tosufloxacin-treated mice was below the detectable limit (Ͻ1.3 log CFU/g). For murine respiratory infection with H. influenzae TUM8, the recovery of bacteria from the trachea and lungs of untreated mice ranged from 6.5 to 5.8 log CFU/g (Fig. 1) . Treatment with CS-940 and sparfloxacin at a dose of 0.63 mg/kg caused a drastic reduction in the number of organisms in the lung.
Our results showed that the in vitro activity of CS-940 against respiratory pathogens was almost the same as that of tosufloxacin and was slightly greater than that of sparfloxacin. These results are similar to those in previous reports (1, 7) . In Japan, the main respiratory bacterial pathogens in outpatients are H. influenzae and S. pneumoniae, including penicillin-resistant organisms. The present study confirmed that the therapeutic effects of CS-940 against murine respiratory infection with penicillin-resistant S. pneumoniae were superior to those of sparfloxacin and that against murine respiratory infection caused by H. influenzae they were superior to those of tosufloxacin. In addition, the ED 50 of CS-940 against murine sepsis caused by intranasal instillation of penicillin-sensitive S. pneumoniae was the smallest among the test drugs. The in vivo activity of CS-940 was greater than that of the reference drug. However, the MICs of CS-940 against organisms used in the in vivo experiments were similar to those of tosufloxacin and sparfloxacin.
Ratios of AUC in lung to AUC in serum and of C max in lung to C max in serum for CS-940, sparfloxacin, and levofloxacin were 2.21 and 1.98, 1.06 and 1.18, and 1.42 and 0.83, respec- b Bordet Gengou agar (Difco) supplemented with 15% horse blood and 1% glycerol was used, and the mixture was incubated at 35°C for 48 h. The MICs were determined by the agar dilution method with an inoculum of 10 4 CFU per spot. tively. These results indicate that the transmigration rate of CS-940 from the bloodstream (serum) to the lungs in mice infected with S. pneumoniae may be higher than those of sparfloxacin and levofloxacin. Based on these results, not only the high level of antibacterial activity in vitro but also good tissue distribution might influence the efficacy of CS-940 in murine models of respiratory infection caused by H. influenzae and S. pneumoniae.
In conclusion, our results indicate that CS-940 is a promising new oral fluoroquinolone for the treatment of respiratory infections caused by gram-negative as well as gram-positive bacteria including penicillin-resistant S. pneumoniae. The drug appears to have no serious side effects.
FIG. 1. Effects of CS-940
and comparable drugs on the recovery of H. influenzae TUM8 from the trachea and lungs of mice with experimentally induced bronchopneumonia. A challenge dose of 9.9 ϫ 10 3 CFU was intranasally instilled into mice, and an antibiotic dose of 0.63 mg/kg was administered orally twice a day for 3 days, starting 36 h after infection. The MICs of CS-940, ciprofloxacin, tosufloxacin, sparfloxacin, and levofloxacin were 0.008, 0.016, 0.008, 0.008, and 0.016 g/ml, respectively. ‫,ء‬ P Ͻ 0.05 versus control, ciprofloxacin, and levofloxacin; ‫,ءء‬ lower than the detectability limits; ‫,ءءء‬ P Ͻ 0.05 versus control. The dashed lines indicate the detectability limits.
